Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORFIRINOX in Advanced Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
NCT03772132Phase 2Unknown
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jul 2016
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, irinotecan and oxaliplatin in extrahepatic cholangiocarcinoma (eCCA) and gallbladder carcinoma, sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Progression Free Survival at 1 year. Status: unknown.
02
Drugs
fluorouracilirinotecanoxaliplatin
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT03772132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772132.